Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 8 | 2018 | 392 | 1.870 |
Why?
|
| Venous Thromboembolism | 3 | 2018 | 146 | 1.350 |
Why?
|
| Pharmacy Service, Hospital | 4 | 2020 | 17 | 0.990 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2013 | 127 | 0.640 |
Why?
|
| Patient Discharge | 4 | 2015 | 408 | 0.630 |
Why?
|
| Antipsychotic Agents | 5 | 2015 | 281 | 0.560 |
Why?
|
| Postthrombotic Syndrome | 1 | 2014 | 3 | 0.550 |
Why?
|
| Stockings, Compression | 1 | 2014 | 3 | 0.550 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2013 | 216 | 0.510 |
Why?
|
| Nursing Homes | 8 | 2015 | 531 | 0.510 |
Why?
|
| Fellowships and Scholarships | 2 | 2015 | 60 | 0.490 |
Why?
|
| Hypolipidemic Agents | 1 | 2012 | 35 | 0.460 |
Why?
|
| Warfarin | 4 | 2014 | 101 | 0.460 |
Why?
|
| Primary Prevention | 1 | 2012 | 114 | 0.430 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 150 | 0.420 |
Why?
|
| Thrombosis | 2 | 2010 | 188 | 0.410 |
Why?
|
| Stroke | 3 | 2013 | 858 | 0.410 |
Why?
|
| Pipecolic Acids | 1 | 2010 | 2 | 0.410 |
Why?
|
| Hemorrhage | 5 | 2018 | 217 | 0.410 |
Why?
|
| Antithrombins | 1 | 2010 | 14 | 0.400 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 49 | 0.390 |
Why?
|
| Heparin | 1 | 2010 | 106 | 0.380 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2009 | 4 | 0.380 |
Why?
|
| Students, Pharmacy | 1 | 2009 | 7 | 0.380 |
Why?
|
| Medication Errors | 3 | 2021 | 106 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 482 | 0.340 |
Why?
|
| Homes for the Aged | 4 | 2014 | 147 | 0.340 |
Why?
|
| Pharmacists | 2 | 2021 | 86 | 0.330 |
Why?
|
| Aspirin | 3 | 2013 | 176 | 0.330 |
Why?
|
| Humans | 29 | 2021 | 48588 | 0.290 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 708 | 0.280 |
Why?
|
| Dementia | 3 | 2015 | 174 | 0.250 |
Why?
|
| Drug Utilization | 3 | 2015 | 221 | 0.230 |
Why?
|
| Continuity of Patient Care | 2 | 2014 | 164 | 0.220 |
Why?
|
| Medication Systems | 1 | 2021 | 18 | 0.220 |
Why?
|
| Patient Readmission | 2 | 2015 | 345 | 0.210 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 2020 | 3 | 0.210 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2011 | 62 | 0.210 |
Why?
|
| Electronic Health Records | 2 | 2014 | 273 | 0.200 |
Why?
|
| Patient Safety | 2 | 2020 | 185 | 0.200 |
Why?
|
| Aged | 11 | 2021 | 10798 | 0.190 |
Why?
|
| Premedication | 1 | 2018 | 17 | 0.170 |
Why?
|
| Male | 13 | 2021 | 23090 | 0.170 |
Why?
|
| Rivaroxaban | 2 | 2014 | 13 | 0.170 |
Why?
|
| Dabigatran | 2 | 2014 | 17 | 0.170 |
Why?
|
| Pyridones | 2 | 2014 | 26 | 0.170 |
Why?
|
| Pyrazoles | 2 | 2014 | 60 | 0.160 |
Why?
|
| Female | 13 | 2021 | 26138 | 0.160 |
Why?
|
| Connecticut | 5 | 2015 | 82 | 0.160 |
Why?
|
| Inappropriate Prescribing | 2 | 2014 | 47 | 0.150 |
Why?
|
| Nursing Staff | 2 | 2013 | 41 | 0.150 |
Why?
|
| Transitional Care | 1 | 2015 | 14 | 0.150 |
Why?
|
| Off-Label Use | 1 | 2015 | 13 | 0.150 |
Why?
|
| Quality of Health Care | 3 | 2015 | 470 | 0.150 |
Why?
|
| Societies, Pharmaceutical | 1 | 2015 | 3 | 0.140 |
Why?
|
| Internship, Nonmedical | 1 | 2015 | 2 | 0.140 |
Why?
|
| Medical Informatics | 1 | 2015 | 64 | 0.140 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 4210 | 0.140 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 23 | 0.140 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 75 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 681 | 0.140 |
Why?
|
| Time Factors | 2 | 2013 | 3188 | 0.140 |
Why?
|
| Models, Organizational | 1 | 2015 | 86 | 0.130 |
Why?
|
| Consultants | 1 | 2014 | 12 | 0.130 |
Why?
|
| Office Visits | 1 | 2014 | 41 | 0.130 |
Why?
|
| Dipyridamole | 1 | 2013 | 22 | 0.130 |
Why?
|
| Medical Staff | 1 | 2013 | 17 | 0.130 |
Why?
|
| Drug Monitoring | 2 | 2012 | 97 | 0.130 |
Why?
|
| Administrative Personnel | 1 | 2013 | 32 | 0.130 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 147 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2014 | 292 | 0.130 |
Why?
|
| Research | 1 | 2015 | 185 | 0.120 |
Why?
|
| Ticlopidine | 1 | 2013 | 61 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2013 | 123 | 0.120 |
Why?
|
| Ramipril | 1 | 2012 | 1 | 0.120 |
Why?
|
| Hydrochlorothiazide | 1 | 2012 | 2 | 0.120 |
Why?
|
| Long-Term Care | 2 | 2011 | 163 | 0.120 |
Why?
|
| Atenolol | 1 | 2012 | 7 | 0.120 |
Why?
|
| Psychiatry | 1 | 2014 | 103 | 0.120 |
Why?
|
| Simvastatin | 1 | 2012 | 21 | 0.120 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2012 | 10 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2012 | 121 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2014 | 270 | 0.110 |
Why?
|
| Drug Costs | 1 | 2011 | 53 | 0.110 |
Why?
|
| Medical Order Entry Systems | 1 | 2011 | 45 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 597 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 189 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2011 | 69 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2011 | 123 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2010 | 94 | 0.100 |
Why?
|
| Psychotropic Drugs | 1 | 2010 | 72 | 0.100 |
Why?
|
| Arginine | 1 | 2010 | 107 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 148 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2010 | 118 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2013 | 533 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1154 | 0.090 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 109 | 0.090 |
Why?
|
| Safety Management | 1 | 2010 | 131 | 0.090 |
Why?
|
| Education, Pharmacy | 1 | 2009 | 14 | 0.090 |
Why?
|
| Medication Therapy Management | 1 | 2009 | 26 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2014 | 549 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 176 | 0.090 |
Why?
|
| Hospitalization | 2 | 2021 | 1063 | 0.090 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2007 | 24 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 540 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 532 | 0.080 |
Why?
|
| Communication | 1 | 2011 | 429 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 159 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2007 | 763 | 0.070 |
Why?
|
| Neoplasms | 1 | 2013 | 985 | 0.060 |
Why?
|
| Information Dissemination | 2 | 2015 | 102 | 0.060 |
Why?
|
| International Normalized Ratio | 2 | 2012 | 36 | 0.060 |
Why?
|
| Massachusetts | 2 | 2021 | 2014 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2015 | 716 | 0.050 |
Why?
|
| Middle Aged | 4 | 2021 | 13418 | 0.050 |
Why?
|
| Organizational Culture | 1 | 2020 | 98 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2007 | 3797 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 2032 | 0.040 |
Why?
|
| Half-Life | 1 | 2015 | 62 | 0.040 |
Why?
|
| Schools, Pharmacy | 1 | 2015 | 5 | 0.040 |
Why?
|
| Health Facility Size | 1 | 2015 | 17 | 0.040 |
Why?
|
| Workload | 1 | 2015 | 99 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 236 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 90 | 0.030 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 8 | 0.030 |
Why?
|
| beta-Alanine | 1 | 2013 | 7 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 760 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 59 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 66 | 0.030 |
Why?
|
| Thiophenes | 1 | 2013 | 38 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 361 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2013 | 49 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 415 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2012 | 51 | 0.030 |
Why?
|
| Health Communication | 1 | 2013 | 28 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2015 | 393 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2013 | 155 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 84 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 369 | 0.030 |
Why?
|
| Ontario | 1 | 2011 | 36 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2013 | 548 | 0.030 |
Why?
|
| United States | 2 | 2015 | 6100 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 42 | 0.030 |
Why?
|
| Cost Savings | 1 | 2011 | 45 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 669 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2012 | 463 | 0.030 |
Why?
|
| Telephone | 1 | 2011 | 112 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 1108 | 0.030 |
Why?
|
| Parents | 1 | 2013 | 258 | 0.020 |
Why?
|
| New England | 1 | 2010 | 244 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 488 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 1922 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 240 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2059 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 1571 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 2478 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2237 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 4204 | 0.020 |
Why?
|
| Child | 1 | 2013 | 3658 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 4404 | 0.020 |
Why?
|